Undiscovered Gems In The United States For July 2024
In This Article:
Over the last 7 days, the market has dropped 1.7%, driven by a decline of 4.5% in the Information Technology sector. However, the market is up 17% over the past year and earnings are forecast to grow by 15% annually. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding. Here are three lesser-known stocks that could offer significant opportunities in July 2024.
Top 10 Undiscovered Gems With Strong Fundamentals In The United States
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| River Financial | 131.04% | 17.59% | 20.70% | ★★★★★★ |
| Morris State Bancshares | 14.93% | 0.44% | 7.74% | ★★★★★★ |
| Omega Flex | NA | 2.13% | 4.77% | ★★★★★★ |
| First Northern Community Bancorp | NA | 6.68% | 9.08% | ★★★★★★ |
| Teekay | NA | -8.88% | 49.65% | ★★★★★★ |
| Mission Bancorp | 25.37% | 16.23% | 20.16% | ★★★★★★ |
| FirstSun Capital Bancorp | 27.36% | 10.54% | 30.73% | ★★★★★★ |
| Gravity | NA | 15.31% | 24.42% | ★★★★★★ |
| CSP | 2.17% | -5.57% | 73.73% | ★★★★★☆ |
| FRMO | 0.19% | 6.49% | 15.82% | ★★★★☆☆ |
Let's explore several standout options from the results in the screener.
Ligand Pharmaceuticals
Simply Wall St Value Rating: ★★★★★★
Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on the development and licensing of biopharmaceutical assets worldwide, with a market cap of $1.92 billion.
Operations: Ligand Pharmaceuticals generates revenue primarily from the development and licensing of biopharmaceutical assets, amounting to $118.31 million. The company has a market cap of $1.92 billion.
Ligand Pharmaceuticals has seen earnings grow by 87.7% over the past year, outpacing the industry average of 19.9%. The company is debt-free, a significant improvement from five years ago when its debt-to-equity ratio was 59.6%. Despite recent insider selling and shareholder dilution, Ligand trades at 50.6% below its estimated fair value and forecasts a revenue growth of 19.8% annually.
Meta Data
Simply Wall St Value Rating: ★★★★☆☆
Overview: Meta Data Limited, along with its subsidiaries, provides K-12 after-school education services specializing in young children's mathematics training and FasTrack English services in China and internationally, with a market cap of $374.09 million.
Operations: Meta Data Limited generates revenue primarily from its educational services, amounting to $32.43 million. The company's market cap stands at $374.09 million.